지놈앤컴퍼니

314130KOSDAQ기초 의약물질 제조업

55.5 / 100

Reference Date: 2026-07-24

Financial Score19.5 / 40

News Sentiment20.0 / 25

Momentum6.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is low with sound financial health but ROE is below the industry average. Declined 8.1% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Genom and Company aims to grow into a fully integrated pharmaceutical company by focusing on innovative drug development, utilizing its GNOCLE™ platform to advance pipeline candidates such as the immunotherapy GENA-104 and microbiome-based treatment GEN-001. The company also diversifies its business through CDMO services and its microbiome cosmetics brand 'UIQ'.

Number of Employees

96people

Average Salary

60.8M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 25.444.0Point

PBR

1.62Industry Average 1.262.5Point

Higher than industry avg (caution)

ROE

-7.20Industry Average -6.033.5Point

In line with industry avg

Debt Ratio

6.62Industry Average 6.624.0Point

In line with industry avg

Trend 2023~20255.5 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲41.3% (2-year basis)

Operating Profit Growth Rate

2.5 / 3

Avg ▲17.6% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -23.6% (improving, 3yr)

Detailed News Sentiment

11 totalPositive 10Neutral 1Negative 0Average Sentiment Score 80

Positive
'바이오 유망주' 넥스아이·아델, 나란히 코스닥 노크
넥스아이와 아델의 코스닥 상장 도전은 기술적 성과와 대규모 투자로 긍정적인 시장 반응을 기대케 한다.
Positive
지놈앤컴퍼니, 전환우선주 128만주 보통주 전환청구
지놈앤컴퍼니의 전환우선주 청구로 인해 주식 발행 규모가 증가하여 재무 건전성 강화 기대.
Positive
뷰티로 번 돈 신약 R&D에… 지놈앤컴퍼니, ADC 성과낼지 ‘관심’
지놈앤컴퍼니는 뷰티 사업 성공으로 인한 현금흐름을 신약 R&D에 재투자하여 ADC 파이프라인의 성과에 대한 기대감을 높이고 있다.

Detailed Momentum

52-week position3.0Point

52w lower range (21%)

Current 4,095Won52-week high 9,97052-week low 2,465

1-month return1.0Point

1m -8.08% (falling)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

5 totalPositive 0Neutral 5Negative 0

Neutral기타경영사항(자율공시) (전환우선주의 보통주 전환청구)2026-07-20
Neutral기타경영사항(자율공시) (전환우선주의 보통주 전환청구)2026-07-14
Neutral기타경영사항(자율공시) (전환우선주의 보통주 전환청구)2026-07-13
Neutral주주명부폐쇄기간또는기준일설정2026-07-10
Neutral주주총회소집결의 (임시주주총회)2026-07-10